← Back to Search

Other

A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer

Phase 1
Waitlist Available
Research Sponsored by InventisBio Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new drug called D-0502 alone and with another drug, palbociclib, in women with a specific type of advanced breast cancer. The goal is to see if these drugs are safe and effective by blocking signals that help cancer cells grow.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: D-0502 in combination with palbociclibExperimental Treatment2 Interventions
D-0502 in combination with palbociclib
Group II: D-0502Experimental Treatment1 Intervention
D-0502
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
palbociclib
2020
Completed Phase 2
~1230
D-0502
2018
Completed Phase 1
~240

Find a Location

Who is running the clinical trial?

InventisBio Inc.Lead Sponsor
7 Previous Clinical Trials
699 Total Patients Enrolled
1 Trials studying Breast Cancer
14 Patients Enrolled for Breast Cancer
InventisBio Co., LtdLead Sponsor
19 Previous Clinical Trials
1,638 Total Patients Enrolled
1 Trials studying Breast Cancer
14 Patients Enrolled for Breast Cancer

Media Library

D-0502 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT03471663 — Phase 1
Breast Cancer Research Study Groups: D-0502, D-0502 in combination with palbociclib
Breast Cancer Clinical Trial 2023: D-0502 Highlights & Side Effects. Trial Name: NCT03471663 — Phase 1
D-0502 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03471663 — Phase 1
~26 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top